trending Market Intelligence /marketintelligence/en/news-insights/trending/3pYfUlgE369Dh-401jsIeQ2 content esgSubNav
In This List

Abbott exercises option to acquire Cephea Valve Technologies

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Abbott exercises option to acquire Cephea Valve Technologies

Abbott Laboratories exercised its option to acquire privately held medical device company Cephea Valve Technologies Inc.

Abbott had first invested in the developer of heart valve replacement technology in 2015, having secured an option at the time to fully buy the business for undisclosed terms in the future. The same year, Abbott also acquired Tendyne Holdings Inc., which develops devices to replace the mitral valve in the heart.

Cephea Valve's technology eliminates the need for open-heart surgery in patients with a diseased mitral valve, which is responsible for blood flow into the heart's left ventricle, the main pumping chamber.

Abbott has been marketing products for mitral valve disease ever since it acquired Evalve Inc. in 2009, which developed MitraClip to repair leaky heart valves.

Abbott ultimately ended up acquiring St. Jude Medical Inc. for $25 billion in 2017, adding to the company's offerings to treat structural heart disease.